San Bruno, CA. May 21, 2015. PRC Clinical, the Clinical Trial Management CRO, is officially joining the Alliance for Regenerative Medicine (ARM). The ARM counts more than 200 pioneering organizations, fostering research, development, investment, and commercialization of transformational treatments and cures for patients worldwide.
PRC Clinical, the California-based CRO focused in Clinical Trial Management, has developed a strong expertise in stem cell and regenerative research working with sponsors in the United States and Israel. “We believe regenerative medicine holds exciting potential to resolve unmet medical needs of untreatable diseases and possibly ease the burdens of an aging population” states Curtis Head, CEO at PRC Clinical. “Joining ARM is one more way for PRC to express our commitment to developing highly innovative therapies for the human condition and beyond.”
Regenerative Medicine is focused on the development and application of cell-based therapies and related technologies to enhance the natural healing process, and/or replace or regenerate organs and tissues. Delivering cures through regenerative medicine requires coordination amongst a broad range of stakeholder groups from industry, academia, government, healthcare professionals, the investment community and consumer advocates. ARM members include leading pharmaceutical companies such as Pfizer, Johnson & Johnson and Novartis, as well as innovative life science companies, research institutions, capital providers, foundations, associations, and patient advocates.
PRC Clinical will attend ARM’s 2015 Stem Cell Meeting on the Mesa on October 7-9 2015 in La Jolla, California. This annual meeting attracts more than 800 industry-leading professionals for partnering opportunities, interactive panels, and scientific lectures.
About PRC Clinical
PRC Clinical is a Silicon Valley-based CRO specializing in Clinical Trial Management, supporting phase I-IV clinical studies for pharmaceutical and medical device companies in 19 countries. Founded in 2003, PRC Clinical offers Clinical Trial Management services including Site Monitoring, Quality Assurance, Drug Safety, Clinical Project Management, Payment Services, Biostatistics, Data Management, and CTMS. PRC clinical has significant CRO experience in conducting phase I-IV clinical studies in a wide range of therapeutic areas: CNS, Neurology, Pain, GI, Device, Anti-infective, Cardiovascular, Pulmonary, Oncology, Endocrine, ALS, Parkinson’s, and Stem cells. Contact us at 1-877-519-6001, or email info@prcclinical.com.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is the preeminent global advocate for regenerative and advanced therapies. ARM fosters research, development, investment and commercialization of transformational treatments and cures for patients worldwide. By leveraging the expertise of its membership, ARM empowers multiple stakeholders to promote legislative, regulatory and public understanding of, and support for, this expanding field. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.
Help employers find you! Check out all the jobs and post your resume.
PRC Clinical, the California-based CRO focused in Clinical Trial Management, has developed a strong expertise in stem cell and regenerative research working with sponsors in the United States and Israel. “We believe regenerative medicine holds exciting potential to resolve unmet medical needs of untreatable diseases and possibly ease the burdens of an aging population” states Curtis Head, CEO at PRC Clinical. “Joining ARM is one more way for PRC to express our commitment to developing highly innovative therapies for the human condition and beyond.”
Regenerative Medicine is focused on the development and application of cell-based therapies and related technologies to enhance the natural healing process, and/or replace or regenerate organs and tissues. Delivering cures through regenerative medicine requires coordination amongst a broad range of stakeholder groups from industry, academia, government, healthcare professionals, the investment community and consumer advocates. ARM members include leading pharmaceutical companies such as Pfizer, Johnson & Johnson and Novartis, as well as innovative life science companies, research institutions, capital providers, foundations, associations, and patient advocates.
PRC Clinical will attend ARM’s 2015 Stem Cell Meeting on the Mesa on October 7-9 2015 in La Jolla, California. This annual meeting attracts more than 800 industry-leading professionals for partnering opportunities, interactive panels, and scientific lectures.
About PRC Clinical
PRC Clinical is a Silicon Valley-based CRO specializing in Clinical Trial Management, supporting phase I-IV clinical studies for pharmaceutical and medical device companies in 19 countries. Founded in 2003, PRC Clinical offers Clinical Trial Management services including Site Monitoring, Quality Assurance, Drug Safety, Clinical Project Management, Payment Services, Biostatistics, Data Management, and CTMS. PRC clinical has significant CRO experience in conducting phase I-IV clinical studies in a wide range of therapeutic areas: CNS, Neurology, Pain, GI, Device, Anti-infective, Cardiovascular, Pulmonary, Oncology, Endocrine, ALS, Parkinson’s, and Stem cells. Contact us at 1-877-519-6001, or email info@prcclinical.com.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is the preeminent global advocate for regenerative and advanced therapies. ARM fosters research, development, investment and commercialization of transformational treatments and cures for patients worldwide. By leveraging the expertise of its membership, ARM empowers multiple stakeholders to promote legislative, regulatory and public understanding of, and support for, this expanding field. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.
Help employers find you! Check out all the jobs and post your resume.
